×
Back to Agenda
Module 5: Phase 3 and Regulatory Review (continued)
Session Chair(s)
Eileen Girten, MS
Medical Writing Therapeutic Area Lead
Pfizer Inc, United States
- NDA Preparation
- Review Clock
- FDA Questions/Requests for Data
- Label Negotiation Centralized Procedure
- De-centralized Procedure
- Mutual Recognition
- Devices
Have an account?